Halozyme Therapeutics Inc. (HALO) confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of ...

Halozyme intends to purchase all the shares of Evotec at 11 euros per share, which represents a premium of 27.5% to Evotec's last close price. U.S.-listed shares of Evotec were up 6.3%, while those of ...

Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.) ...

Germany’s Evotec SE has attracted takeover interest from Nasdaq-listed biotech firm Halozyme Therapeutics Inc. for a deal ...

Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team Storage-Area Networking (SAN) DIEGO, ...

Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, ...

German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday.

ADRs quickly rose 14% on a report that Halozyme Therapeutics (HALO) has expressed takeover interest. Halozyme has recently ...

Evotec stock surges 10% as Halozyme Therapeutics expresses takeover interest, sparking investor excitement and speculation in ...

Evotec price target lowered to EUR 11.60 from EUR 12 at RBC Capital Evotec rallies after Bloomberg says Triton weighing takeover bid Evotec Reports Strategic Growth Amidst Revenue Challenges Evotec AG ...